Program
toripalimab
Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.
Drug pageToripalimab: every studyMany companies study it; this page follows only the 13 they lead. All 362 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGenits history only | 54 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Mabwell (Shanghai) Bioscienceits history only | 33 open or running | phase 3since Sep 9, 2024 | Sep 25, 2023 | Dec 31, 2026phase 2 · NCT06079112 |
| Coherus Oncologyits history only | 22 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| Suzhou Zelgen Biopharmaceuticalsits history only | 21 open or running | phase 2since Aug 3, 2020 | Aug 3, 2020 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 3since Dec 12, 2018 | Dec 12, 2018 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named toripalimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JS001
- Dec 12, 2018First study: phase 3 study in Triple Negative Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03777579 · 375 enrolled · China
- Aug 3, 2020Suzhou Zelgen Biopharmaceuticals’ first study: phase 2 study in Advanced Hepatocellular CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT04503902 · 46 enrolled · China
- Oct 21, 2020Phase 1 study in Unresectable Hepatocellular CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT04605185 · 18 enrolled · China
- Mar 17, 2022RemeGen’s first study: phase 2 study in Muscle Invasive Bladder CarcinomaNew to RemeGenRemeGen · NCT05297552 · 40 planned · China
- Sep 1, 2023Phase 2 study in Advanced Solid TumorRemeGen · NCT06038396 · 48 planned · China
- Sep 25, 2023Mabwell (Shanghai) Bioscience’s first study: phase 2 study in Advanced Urothelial CarcinomaNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT06079112 · 100 planned · China
- Oct 23, 2023Phase 2 study in Breast NeoplasmsRemeGen · NCT06105008 · China
- Nov 23, 2023Phase 2 study in Stomach NeoplasmsRemeGen · NCT06155383 · 90 planned · China
- Jan 17, 2024Phase 2 study in Breast NeoplasmsRemeGen · NCT06227117 · 120 planned · China
- Jun 10, 2024Coherus Oncology’s first study: phase 4 study in Nasopharyngeal NeoplasmsNew to Coherus OncologyCoherus Oncology · NCT06457503 · 100 planned · United States, Canada
- Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326 · 460 planned · China
- Oct 23, 2024Phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144 · 154 planned · United States, Taiwan
- Jan 13, 2025Phase 2 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06823427 · 60 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112
- Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326
- Dec 2027Primary completion: phase 4 study in Nasopharyngeal NeoplasmsCoherus Oncology · NCT06457503
- Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06823427Carcinoma, Transitional Cell · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Jun 2026 | 60 |
| NCT06657144Neoplasm Metastasis · United States, Taiwan | 1 | Recruiting | Coherus Oncology | Jan 2028 | 154 |
| NCT06592326Carcinoma, Transitional Cell · China | 3 | Recruiting | Mabwell (Shanghai) Bioscience | Sep 2027 | 460 |
| NCT06457503Nasopharyngeal Neoplasms · United States, Canada | 4 | Recruiting | Coherus Oncology | Dec 2027 | 100 |
| NCT06227117Breast Neoplasms · China | 2 | Recruiting | RemeGen | Dec 2025 | 120 |
| NCT06155383Stomach Neoplasms · China | 2 | Recruiting | RemeGen | Jan 31, 2025 | 90 |
| NCT06105008Breast Neoplasms · China | 2 | Withdrawn | RemeGen | Dec 20, 2025 | 0 |
| NCT06079112Advanced Urothelial Carcinoma · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2026 | 100 |
| NCT06038396Advanced Solid Tumor · China | 2 | Recruiting | RemeGen | Feb 28, 2026 | 48 |
| NCT05297552Muscle Invasive Bladder Carcinoma · China | 2 | Recruiting | RemeGen | Jun 1, 2024 | 40 |
| NCT04605185Unresectable Hepatocellular Carcinoma · China | 1 | Active, not recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2024 | 18 |
| NCT04503902Advanced Hepatocellular Carcinoma · China | 2 | UNKNOWN | Suzhou Zelgen Biopharmaceuticals | Dec 2023 | 46 |
| NCT03777579Triple Negative Breast Neoplasms · China | 3 | Suspended | CSPC Pharmaceutical Group | Dec 30, 2019 | 375 |
How it is read
Names in the registry
- “Toripalimab”, 14 entries
- “Toripalimab Injection”, 3 entries
- “CM082 plus JS001”, 3 entries
- “ABO2109 Injection;Toripalimab”, 2 entries
- “JS001”, 2 entries
Codes read as this program: JS001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 3 studies
- Melanoma, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Transitional Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.